Project background and main business challenges
A Swedish group with 23 factories and 3,500 employees around the world, Recipharm in Kayserberg specializes in ophthalmic solutions. A year and a half after being bought from Novartis, the company was investing €18m to expand the site’s production capacity, and anticipating the planned transfer of its information system when the Kayserberg sale was completed.
Its Blow Fill Seal® technology is used to shape, fill and seal vials using just one machine, making productions conditions perfectly aseptic. Its products, ophthalmic drops in single-dose packaging, are currently sold almost exclusively to its customer Alcon.
As part of its investment, 1,100m² will be redeveloped, being the capacity of four new production lines. The first production line entered service at the end of 2017, allowing the company to climb from 400 to 600 million units output per annum.